Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

BACKGROUND: Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yifeng, Su, Peiling, Sun, Yifan, Zhang, Hongsheng, Zhao, Rong, Li, Liang, Meng, Lanfen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574209/
https://www.ncbi.nlm.nih.gov/pubmed/28841848
http://dx.doi.org/10.1186/s12882-017-0691-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574209/
https://www.ncbi.nlm.nih.gov/pubmed/28841848
http://dx.doi.org/10.1186/s12882-017-0691-6

Ejemplares similares